Сariprazine in the treatment of schizophrenia spectrum disorders in a hospital setting
https://doi.org/10.31363/2313-7053-2023-868
Abstract
The aim of the study was to evaluate the possibility of using cariprazine for the treatment of productive and negative symptoms in schizophrenic spectrum disorders in a hospital setting.
Materials and methods: A group of 35 patients with leading productive and negative symptoms in patients with schizophrenic spectrum disorders treated in a psychiatric hospital constituted the material of the study. The condition of patients was objectified according to the Clinical Global Impression Scale (CGI-S and CGI-I) and the Positive and Negative Syndrome Scale (PANSS) — at the beginning of the study and in dynamics on the 30th and 60th day of treatment. The mean PANSS score at the beginning of the study was 94.45±14.49 points. After the drug administration, the patients were followed up for up to 60 days.
Results: Cariprazine was administered both as first-line treatment and after prior therapy. The dose range was from 1.5 mg to 6 mg daily. In 3 patients (8.57%), cariprazine therapy was discontinued due to the development of adverse events or worsening of the condition. The remaining 32 patients (91.43%) showed positive dynamics.
Conclusions: The study showed high efficacy of cariprazine when administered for the treatment of productive and negative symptoms in schizophrenic spectrum disorders in a hospital setting. The drug was well tolerated in the majority of patients.
About the Authors
O. V. Limankin
Psychiatric Hospital No. 1 named after P.P. Kaschenko
Russian Federation
Russian Federation
Oleg V. Limankin
Saint Petersburg
K. K. Koniushenko
Psychiatric Hospital No. 1 named after P.P. Kaschenko
Russian Federation
Russian Federation
Konstantin K. Koniushenko
Saint Petersburg
L. P. Linova
Psychiatric Hospital No. 1 named after P.P. Kaschenko
Russian Federation
Russian Federation
Lidiya P. Linova
Saint Petersburg
M. V. Bernikov
Psychiatric Hospital named after N.N. Solodnikov
Russian Federation
Russian Federation
Mihail V. Bernikov
Omsk
E. A. Golosov
Psychiatric Hospital No. 1 named after P.P. Kaschenko
Russian Federation
Russian Federation
Egor A. Golosov
Saint Petersburg
A. V. Bugorskij
Psychiatric Hospital No. 1 named after P.P. Kaschenko
Russian Federation
Russian Federation
Aleksandr V. Bugorskij
Saint Petersburg
References
1. Инструкция по препарату «Реагила» рег. №: ЛП-(001510)-(РГ-RU) от 06.12.22. [grls.minzdrav.gov.ru].grls; 2022. Доступно: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=888732b8-f07d-4c3c-ab9c-e4e9c65b119e
2. Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Nemeth G, Migliore R, Volk S. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl). 2017;234(2):199-209. https://doi.org/10.1007/s00213-016-4450-3
3. Fleischhacker W, Galderisi S, Laszlovszky I, Szatmári B, Barabássy Á, Acsai K, Szalai E, Harsányi J, Earley W, Patel M, Németh G. THe efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1-9. https://doi.org/10.1016/j.eurpsy.2019.01.015.
4. Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019;29(1):127-136. https://doi.org/10.1016/j.euroneuro.2018.10.008.
5. Németh G, Laszlovszky I, Czobor P, Szalai E, Szatmári B, Harsányi J, Barabássy Á, Debelle M, Durgam S, Bitter I, Marder S, Fleischhacker WW. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103-1113. https://doi.org/10.1016/S0140-6736(17)30060-0.
6. Stahl SM, Laredo S, Morrissette DA. Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. THerapeutic Advances in Psychopharmacology. 2020;10. https://doi.org/10.1177/2045125320905752
Review
For citations:
Limankin O.V., Koniushenko K.K., Linova L.P., Bernikov M.V., Golosov E.A., Bugorskij A.V. Сariprazine in the treatment of schizophrenia spectrum disorders in a hospital setting. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2023;57(3):92-97. (In Russ.) https://doi.org/10.31363/2313-7053-2023-868
Views:
575
Email this article 